Abstract Background: Musculoskeletal tumor imaging is a focused subspecialty of musculoskeletal radiology. The goals of imaging and techniques employed are continually evolving and often slightly different from those used in other musculoskeletal diseases. As these techniques change, it is occasionally useful to review what is new. Questions/Purposes: The question addressed in this manuscript is what are the most interesting/relevant changes in each modality of musculoskeletal tumor imaging over the past 38 years, the length of time the newly emeritus chair of the Radiology and Imaging Department of Hospital for Special Surgery has been at the hospital. Methods: This review is primarily expert opinion based in examining techniques used at the institutions of the authors, with support from current literature. Results: The techniques of computed tomography (CT) and magnetic resonance imaging (MRI) are new to the imaging armamentarium, and ultrasound and nuclear medicine techniques have advanced considerably with technology. Although radiographs have also evolved, the changes are less apparent, except in how they are currently processed, viewed, and stored. Conclusions: Radiographic evaluation is still critical to evaluating bone tumors. Newer techniques also play an important role in diagnosing and treating these neoplasms.
Introduction
This paper looks at advances in imaging that affect the diagnosis and treatment of orthopedic oncology, especially neoplasms of bone. As a tribute to Dr. Helene Pavlov's 38-year tenure at Hospital for Special Surgery (HSS), the article looks at changes since her arrival.
The imaging of bone tumors in the early 1970s relied heavily on radiographs. Other modalities supplemented information gained by radiographs. Bone scintigraphy (bone scans) could help stage the tumor, and angiography could help define it. There was plain tomography and fluoroscopy. Early ultrasound produced grainy images. Arthrography and myelography could show lesions in joints and the spine, respectively, but there was no way to give a three-dimensional look. Tissue characterization and staging were very basic.
Imaging now comprises a larger and more technologically advanced armamentarium that includes computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and nuclear imaging (including positron emission tomography (PET)). With newer techniques in mind, the authors seek to answer the question, "What are the most current and interesting changes in bone tumor imaging?"
Methods
General Pubmed searches resulted few productive results [15] . We therefore focused on specific topics of tumor imaging, such as 18 F PET, that we or others use in their practices in order to provide current and accurate information about those topics. This article is therefore heavily weighted toward expert opinion.
Results and Discussion

X-rays and the Digital Format
Radiographs remain the most important imaging test for diagnosing bone tumors. They use a specific energy of photon-x-rays, which have a higher energy and shorter wavelength than visible light. Although used at HSS since 1899, major changes have taken place in their production and their viewing/storage [21] . Now, radiographs are obtained digitally-either by exposing a plate that is subsequently transferred to a digital format (CR) or directly creating an electronic image (DR). The digital images can then be electronically stored, viewed, and shared. The digital format allows easier manipulation of the image, including brightness, contrast, rotation, enlargement, and digital measurement.
Radiographs continue to allow characterization of distribution, matrix, and often aggressiveness. Many bone lesions have very characteristic appearances (e.g., Paget's disease, osteochondromas, osteosarcoma, and fibrous dysplasia) (Figs. 1 and 2). Others have typical locations (non-ossifying fibroma, adamantinoma, and giant cell tumor of bone) (Fig. 3a) . Many are more common in certain age groups (Ewing's sarcoma and unicameral bone cyst) (Fig. 4) . Other imaging techniques sometimes supplement radiographs to solve problems, define the lesion, or plan or evaluate treatment (Fig. 3) [11] .
Fluoroscopy
Fluoroscopy produces real-time images on a screen using xrays. Conventional (in distinction to CT or MRI) angiography is performed using fluoroscopy. Many use fluoroscopy to guide procedures, but it has little use in bone tumor imaging, except to localize bone tumors at the time of surgery and for angiography used in chemo-embolization treatments and preoperative embolization of vascular tumors (Fig. 5) [5, 13, 16] . 
Computed Tomography
CT is an x-ray technique that takes images at very thin (less than 1 mm) intervals to produce detailed information for 3-D modeling and 3-D printing. CT is useful for detailed evaluation of bone and detection of subtle calcifications, important to the differential diagnosis of tumors. Bone tumors will also ossify as they heal, allowing CT to evaluate treatment response (Figs. 6 and 7) [18] .
CT-guided procedures allow the accurate placement of needles in three planes for biopsies, even of the smallest visible lesions (Fig. 8 ) [19] . It also guides probes for tumoral ablation with ultrasound radiofrequency, microwave, chemical, or cryo-ablation [20] . 
Magnetic Resonance Imaging
MRI uses a strong magnet along with radiofrequency pulses to produce very detailed anatomic images of the body. MRI technology continues to advance since its introduction to clinical practice in the 1980s. MRI can be used to define, characterize, and follow tumors, as well as guide needles for diagnosis and treatment [17, 23] .
After x-ray, MRI has become the primary test used to evaluate musculoskeletal tumors [3] . It is often no more helpful than the x-ray in histologic diagnosis, except in the case of certain lesions such as aneurysmal bone cysts and chondroid tumors (Figs. 3 and 9 ), but is able exquisitely to detail a primary tumor's extent (Fig. 10) .
MRI is very sensitive to the presence of fat, to characterize lesions containing fat and to identify bone marrow abnormalities ( Fig. 10 ). It can be used effectively to screen the whole body for focal abnormalities/tumors such as myeloma or metastatic disease [14] .
MRI has a role in evaluating response to treatment, both in size and extent of necrosis (Fig. 11) [2, 18] . Potential exists to use MRI to distinguish certain tumors and aggressiveness based on spectral footprint, but this work has been clinically disappointing. The future holds potential for molecular markers, which can be used for tagged treatments nuclear medicine detection, and association with MRI [7] .
Another role for MRI is its ability to produce angiograms. MR angiography (MRA) can evaluate blood flow to a lesion and thus the suitability of treatment with isolated limb perfusion and permits noninvasive follow-up of treatment [26] .
Ultrasound
Ultrasound imaging was introduced to clinical practice in the 1960s. It is a noninvasive and inexpensive imaging modality to detect a lesion, pinpoint location, establish vascularity, and determine if it is cystic or solid (Fig. 12) . Since the ultrasound beam cannot penetrate the bone, it is more useful in soft tissue lesions. However, it is effective in detecting extraosseous tumor extension and guiding biopsy or procedures.
In the past decade, image-fusion and coregistration technology have increased the power of imaging for identification of lesions and treatment guidance, as well as the potential to improve accuracy of procedures (Fig. 13) In coregistration, images can be fused into a single display [1] . Coregistration can be either simultaneous, such as in PET-CT-or MRI-guided ultrasound treatments, or nonsimultaneous [1] .
Nuclear Medicine
Nuclear medicine relies on physiology and biology rather than anatomy, so-called functional imaging. Bioactive radioactive substances (radiopharmaceuticals) are injected into patients. Detection of the radioactivity can produce two-or three-dimensional images.
Typical agents used for skeletal tumor imaging include 99m Tc-methylene diphosphonate ( 99m Tc-MDP), which goes to metabolically active/forming bone and is typically used in bone scans; 18 [F]-2-fluoro-2-deoxy-D-glucose ( 18 F-FDG), which goes to areas that are actively processing glucose; and fluorine-18-labeled NaF ( 18 F-NaF), which mimics phosphate and is highly sensitive in detecting boneforming processes [8] .
99m Tc-MDP bone scan is effective in detecting boneforming benign and malignant processes such as fractures and osteoblastic metastases (Fig. 14) and can image the entire skeleton, useful for detection of multiple lesions. However, 99m Tc-MDP bone scan is less successful in detecting certain tumors that cause rapid bone destruction or preventing local repair, such as thyroid metastases and multiple myeloma.
Flare phenomenon can affect 99m Tc-MDP bone scan's assessment of tumor response to therapy. An increased uptake of the radioactive substance can be detected up to 6 months after treatment of bone metastases [6, 22] . Distinguishing flare phenomenon from disease progression is challenging and often requires additional evaluation with other imaging modalities such as MRI. and d) , the tumor has not only become smaller, the character has changed to lack enhancement in the bone (arrow) and soft tissue. At surgery, the tumor had responded to chemotherapy and was 90% fibrotic. The 1970s was groundbreaking for nuclear medicine, as PET technology and synthesis of 18 F-FDG became available [10, 24] . In 1999, a combined PET and CT scanner was introduced [4] . With advances in PET and CT technologies, 18 F-FDG-PET has become the dominant oncologic imaging modality in diagnosis, staging, and treatment response of primary bone tumors as well as osseous metastases. Because the metabolism of 18 F-FDG is similar to that of glucose, 18 F-FDG accumulates in malignant cells with a high glycolytic/ metabolic rate. In staging, 18 F-FDG-PET is potentially more sensitive and specific than bone scan for detection of osseous metastases (Fig. 15) [9] . 18 F-FDG-PET is also useful for evaluating eventual therapeutic response and detection of local recurrence. Low uptake in osteosarcoma has correlated with favorable histologic response [25] . 18 F-FDG-PET is less useful in evaluating body parts that normally have high uptake of the pharmaceutical, such as bowel, bladder, and bone marrow.
There has been recent interest in 18 F-NaF PET in tumor imaging [8] . Although the 18 F-NaF agent has a biodistribution similar to the 99m Tc-MDP, there are major advantages of 18 F-NaF PET over 99m Tc-MDP bone scan [12] . They include earlier image acquisition Fig. 16 . Local recurrence of parosteal osteosarcoma and lung metastasis at 18 F-NaF PET. a Axial CT image shows multiple bone-forming masses (arrows) at the left thigh. b Axial PET image show substantially higher radiotracer uptake in the masses (arrows), compared to the uptake in the normal right femur, and histologic diagnosis confirmed recurrent osteosarcoma. c Axial CT image shows a small right upper lung nodule (arrow) and post surgical pneumothoraces (asterisk) after resection of left pulmonary metastases. d Axial PET image demonstrates intense radiotracer uptake in the nodule consistent with a bone-forming metastasis. Fig. 15 . Osseous metastatic Ewing sarcoma at PET scan and bone scan. a FDG uptake foci (arrows) at L2 and right superior acetabulum are present at metastases in pre treatment scan. b One month after chemotherapy, FDG activity is significantly decreased in metastases (arrows). Increase in FDG uptake in remainder spine and pelvis is compatible with red marrow hyperplasia. c Post therapy bone scan shows radiotracer uptake at L2 and right acetabulum without significant change compared to pre therapy bone scan (not shown).
(<1 h compared to 2-3 h), shorter imaging time, faster clearance of radiotracer, and higher spatial image resolution [8] . Because of high sensitivity to detection bone-forming process in skeleton and soft tissue, 18 FNaF PET is potentially useful in staging and following bone-forming malignancies such as osteosarcoma and osteoblastic osseous metastases (Figs. 16 and 17 ) [12] .
Conclusion
Radiology is an exciting field because it is technology driven and continues to change. This is also true of orthopedic tumor imaging. Each modality discussed in this paper has either come into existence or undergone remarkable changes in the past 40 years, but it is 
